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Abstract 
‘Click chemistry’ was explored to synthesize two series of 2-(1,2,3-triazolyl) adenosine 
derivatives (1-14). Binding affinity at the human A1, A2A and A3ARs (adenosine receptors) and 
relative efficacy at the A3AR were determined. Some triazol-1-yl analogues showed A3AR 
affinity in the low nanomolar range, a high ratio of A3/A2A selectivity and a moderate-to-high 
A3/A1 ratio. The 1,2,3-triazol-4-yl regiomers typically showed decreased A3AR affinity. 
Sterically demanding groups at the adenine C2 position tended to reduce relative A3AR efficacy. 
Thus, several 5-OH derivatives appeared to be selective A3AR antagonists, i.e. 10, with 260-fold 
binding selective in binding in comparison to the A1AR and displaying a characteristic docking 
mode in an A3AR model. The corresponding 5-ethyluronamide analogues generally showed 
increased A3AR affinity and behaved as full agonists, i.e. 17, with 910-fold A3/A1 selectivity. 
Thus, N6-substituted-2-(1,2,3-triazolyl) adenosine analogues constitute a novel class of highly 
potent and selective nucleoside-based A3AR antagonists, partial agonists and agonists. 
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Introduction 
Adenosine receptors (AR) are G protein-coupled receptors and consist of four subtypes classified 
as A1, A2A, A2B and A3. Among the four AR subtypes, the A3AR is the most recently identified.1 
The distribution of A3AR is species-dependent and in humans this subtype occurs in the lungs, 
liver, heart, kidneys, and brain.2-4 Activation of this receptor subtype inhibits adenylyl cyclase 
activity, increases phosphatidylinositol-specific phospholipase C activity, and stimulates Ca2+ 
mobilization.3 Adenosine A3 receptor stimulation induces cardioprotection through the activation 
of KATP channels4 and is also involved in neuroprotection, suggesting the possibility of using 
A3AR agonists to treat cardial and cerebral ischemia.5 A3AR agonists also exhibit systemic 
anticancer and chemoprotective effects.6 A3AR modulators have been proposed as 
antiinflammatory and antiasthmatic drugs.7,8 Selective A3AR antagonists promise to be useful in 
the regulation of cell growth8,9 and as cerebroprotective agents.10,11 They also seem to enhance 
anticancer treatment by counteracting P-glycoprotein efflux in multidrug resistance.12 A3AR 
antagonists are also proposed as potential therapeutics for the treatment of glaucoma; application 
of A3AR antagonists externally to the eye substantially lowers intraocular pressure in mice and 
monkeys.13-15  
 
Although diverse in structure, most AR antagonists share some common structural features. In 
general, they are planar, aromatic or π-electron rich and nitrogen-containing heterocycles. 
Additionally, most AR antagonists lack the ribose moiety which seems essential for agonist 
activity.16 Various heterocyclic classes have been identified as promising leads for A3AR 
antagonists, among them: 1,4-dihydropyridines, pyridines, deazaadenines, pyrazolopyrimidines, 
adenines, and 1,2,4-triazolo[4,3-a]quinoxalin-1-ones.4,7,17,18  
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However, the A3AR, more than other AR subtypes, is amenable to the design of nucleoside-based 
antagonists. The efficacy of nucleoside derivatives in activation of the A3AR is particularly 
sensitive to molecular substitution of the ligand.19 A wide range of adenosine derivatives have 
been shown to antagonize this receptor, including the highly potent A1AR agonist 2-chloro-N6-
cyclopentyladenosine.  N6-Benzyl groups are associated with reduced A3AR efficacy, leading to 
partial agonists and antagonists. However, many of the nucleosides so far demonstrated to be 
antagonists of the A3AR are not highly subtype selective.20 Nucleoside-based A3AR antagonists 
maintaining an intact ribose moiety were reported by Volpini et al.,21 with a series of 8-alkynyl 
adenosine derivatives that exhibited A3AR selectivity, but suffered from weak A3AR affinity. A 
spirolactam derivative, in which the 5-alkyluronamide group was cyclized onto the 4 carbon, 
was found to potently and selectively antagonize the A3AR.15,19  An advantage of nucleoside-
based A3AR antagonists over other heterocyclic antagonists is the ability to achieve high affinity 
at murine species.   
 
Recently, researchers from CV Therapeutics described a series of 2-pyrazolyl-adenosine 
analogues.22 Several representative compounds, containing an N6-methyl substituent proved to 
display high affinity and selectivity for the A3AR. This study confirms the former finding23 that 
introduction of a methyl group into the N6 position increases the affinity for the human A3AR and 
enhances the selectivity versus A1 and A2AARs. Based on these results, we explored the versatile 
‘click chemistry’ approach24 to synthesize two series of N6-methyl-2-(1,2,3-triazolyl) adenosine 
derivatives and evaluated their affinity, selectivity and efficacy at the A3AR. Although a number 
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of 1,2,3-triazole nucleoside derivatives have been described,25 most involve base replacement 
with 1,2,3-triazole, or introduction of 1,2,3-triazole at C-8 or at the sugar moiety.  
 
 
Results and Discussion 
Chemistry 
The synthesis of the 1,2,3-triazol-1-yl adenosine derivatives is depicted in Scheme 1. 2-Iodo-N6-
methyladenosine 2223 was prepared by reacting 2126 with 2.0 M CH3NH2 in THF. Since the 
reaction conditions27 for a Cu(I)-catalysed nucleophilic substitution are very similar to those used 
in the ‘click’ variant of Huisgen’s 1,3-dipolar cycloaddition, we initially attempted to perform a 
one-pot conversion of 22 to the desired 1,4-disubstituted 1,2,3-triazoles. The 2-azido derivative 
23 was isolated as the main reaction product and only a minor amount of the appropriate triazole 
was formed. This event forced us to perform the reaction in two steps. First the azido 
intermediate 23 was prepared in 66% yield from 22. 1H and 13C NMR in DMSO-d6 proved the 
presence of a tautomeric fused tetrazole form (17%) of the 2-azido adenosine derivative 23, due 
to a spontaneous cyclization (Scheme 2). Such azido/tetrazole tautomerism has been previously 
reported for 2-azidoadenine and for 2-azidoadenosine.28,29 Next we applied a Cu(I)-catalysed 1,3-
cycloaddition reaction of azide 23 with the appropriate alkyne to generate the triazole analogues 
1-11 (Scheme 1).30 Generally, the use of a water:butanol mixture as a solvent for the 1,3-
cycloaddition allowed simple isolation of the desired compounds, which precipitated from the 
reaction medium. 
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Similarly, the 1,2,3-triazol-4-yl analogues 12-14 (Scheme 3) were prepared by a Cu+-catalysed 
Huisgen 1,3-dipolar cycloaddition reaction of 2-ethynyl-N6-methyladenosine (25) with the 
appropriate azide. 
The synthesis of the 5-N-ethylcarbamoyl 2-(1,2,3)-triazol-1-yl adenosine analogues 15-19 was 
carried out starting from 2-iodo-9-(2,3-O-isopropylidene--D-ribofuranosyl)-N6-methyladenine 
(26). After permanganate oxidation, carboxylic acid 27 was converted into its p-nitrophenyl ester 
28, which upon treatment with ethylamine gave uronamide 29. Deprotection with 80% 
trifluoroacetic acid yielded 5-ethylcarbamoyl-N6-methyl-2-iodoadenosine (30).30 The conversion 
of this 2-iodo derivative into the azido intermediate 31 was performed in 79% yield. The 
presence of a tautomeric fused tetrazole form (20%) of the 2-azidoadenosine derivative 31, due to 
a spontaneous cyclization was here also observed in the NMR spectrum. Finally we applied the 
Cu(I)-catalysed 1,3-cycloaddition reaction of azide 31 with the appropriate alkyne to generate the 
triazole analogues 15-19 (Scheme 4). 
2-Azido-N6-(5-chloro-2-methoxybenzyl)-2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(-D-
ribofuranosyl)adenine (20) was prepared in 3 steps starting from intermediate 21, as depicted in 
Scheme 5. 
 
Biological evaluation. The binding affinities of the newly synthesized adenosine derivatives 
were measured at the hA1, hA2A and hA3ARs expressed in CHO (Chinese hamster ovary) cells as 
previously described,20 and their relative efficacy in the activation of the A3AR was determined 
(Table 1). The binding affinity of more potent compounds at the ARs was evaluated with full 
competition curves, while the weaker compounds at the hA1 and hA2A ARs were measured at a 
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fixed concentration of 10 µM. Several compounds showed affinity for the A3AR in the low 
nanomolar range, a very high ratio of A3/A2A selectivity and a moderate-to-high A3/A1 selectivity 
ratio.  A functional assay of A3AR activation consisted of the ability of a single, high 
concentration of the nucleoside (10 µM) to inhibit forskolin-stimulated adenylyl cyclase 
measured by the method of Nordstet and Fredholm,32 in comparison to the full agonist NECA (10 
µM). Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-5-N-methylcarboxamidoadenosine) was also a 
full agonist (100%) in this assay.19 The range of efficacies observed depended on the nature of 
the groups at the 2 and N6 positions.   
 
The 2-azido precursor 23 showed high binding affinity at the A3AR (Ki = 10.8 nM) and modest 
selectivity in comparison to the A1AR. The 1,2,3-triazol-1-yl derivatives obtained by 1,3-dipolar 
cycloaddition of azide 23 with acetylene (1), butyne (2) and hexyne (3) maintained high affinity 
for the A3AR and increased selectivity. They displayed Ki values of 10.4 nM, 13.8 nM and 11.7 
nM, respectively. Also, aromatic triazole substituents (6, 7, 9) resulted in similar Ki values of 
about 10 nM and even greater selectivity. Introducing nitrogen or oxygen including substituents 
at position 4 of the 1,2,3-triazole ring (4, 5, and 8) reduced the A3AR affinity. Among the 
investigated analogues, the 4-cyclopentylmethyl derivative 10 exhibited the highest affinity for 
the A3AR (Ki = 1.3 nM) and 260-fold selectivity in comparison to the A1AR. Replacement of the 
cyclopentyl ring with a phenyl (9) or cyclohexyl (11) moiety adversely affected A3AR affinity. 
Remarkably, the 1,2,3-triazol-4-yl regiomers (12-14) showed decreased affinity for the A3AR in 
comparison to similar 1,2,3-triazol-1-yl regiomers. In particular, a comparison of homologous 
compounds 12 and 9 indicated a 6-fold loss of affinity at the A3AR for the 4-yl isomer, 
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approximately the same affinity at the A1AR, and no significant measurable gain in affinity at the 
A2AAR.   
   
Replacement of the ribose 4-hydroxymethyl moiety of the 2-azido derivative 23 by a 5-N-
ethyluronamide did not appreciably affect affinity at any of the AR subtypes. However, a similar 
substitution in the 2-(1,2,3-triazol-1-yl)-substituted series provided a modest (2 to 5-fold) 
increase in A3AR affinity and small or no changes in A1AR affinity, as demonstrated for the 
unsubstituted, 4-butyl, 4-pyridin-2-yl and 4-benzyl substituted 1,2,3-triazol-1-yl combinations 
(15 – 18, in comparison to 1, 3, 7, and 9, respectively). Curiously, one 5-uronamide, compound 
19, exhibited decreased A3AR affinity (Ki = 11.5 nM) compared to its potent 5-OH analogue 10 
(Ki = 1.3 nM).  
 
Replacement of the N6-methyl substituent of the 2-azido precursor 23 by a sterically demanding 
2-chloro-5-methoxybenzyl group yielded 33, which manifested very high A3AR affinity (Ki = 1.4 
nM). A similar replacement of the N6-methyl group of an analogue 10, also having a bulky 2 
position substituent, to yield 20, reduced A3AR affinity, but not appreciably. This was in 
accordance with previous observations that a simultaneous substitution at the 6 and 2 positions 
did not improve A3AR affinity.22,33 Thus, the effects of substitution at the 2 and N6 positions were 
not independent, however it was possible to retain considerable A3AR selectivity (46-fold in 
compound 20).  This was not representative of findings in a previous study in which double 
substitution greatly diminished the affinity and selectivity at the human A3AR.22 
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Whereas some previously synthesized 2-substituted adenosine derivatives22,23 displayed selective 
A3AR agonist activity, all 2-triazol-1-yl-N6-methyl adenosine analogues synthesized with an 
unmodified ribose moiety (1-11 and 20) behaved as antagonists or weak partial agonists. Similar 
findings were reported for 2-ester derivatives of adenosine, in which a combination of 2 and N6 
substitution reduced efficacy.34 Direct ring substitution at the 4-position of the 1,2,3-triazole with 
alkyl or aryl groups resulted in weak partial agonists (1, 2, 4-8), but subtle changes of structure 
resulted in a loss of efficacy, e.g. the 4-butyl derivative 3. 2-Triazol-1-yl-N6-methyl-adenosine 
analogues with a methylene spacer between the 1,2,3-triazole moiety and a ring system yielded 
full A3AR antagonists (9-11, 20), since they bound to the receptor but did not activate it. The 2-
triazol-4-yl-N6-methyl-adenosine derivatives (12-14) also behaved as full A3AR antagonists. 
Thus, the 5-OH derivatives 3, 9-14, and 20 appeared to be A3AR antagonists with the following 
order of decreasing selectivity for the A3AR in comparison to the A1AR:  4-cyclopentylmethyl-
N6-methyl 10 (260-fold) > 4-butyl-N6-methyl 3 (72-fold), 4-cyclohexylmethyl-N6-methyl 11 (67-
fold) > 4-cyclopentylmethyl-N6-(5-chloro-2-methoxybenzyl) 20.   
 
Interestingly, the 5--ethyluronamide modification was able to reestablish the A3AR agonist 
activity in analogues with sterically bulky substitution at the 2 position. This is consistent with 
previous findings that similar 5-uronamides overcome the efficacy-reducing activity of 
substitution at the adenine 2 and N6-positions, but not at the ribose 3-position.19,35,36 Indeed, all 
5-ethyluronamide analogues studied here (15-19) proved to be full agonists at the A3AR. 
Among them are highly selective A3AR agonists, N6-methyl-adenosine-5-ethyluronamide 2-
(1,2,3-triazol-1-yl) derivatives:  pyridin-2-yl 17 (910-fold) > unsubstituted 15 (280-fold) > benzyl 
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18 (180-fold). The 2-azido-N6-methyl precursors 23 and 31 also showed full agonist activity, 
whereas azide 33 having a bulky N6 group showed partial agonist activity. 
 
Selected potent agonists in this series were measured in a functional assay of the human A2BAR. 
At a concentration of 10 µM, compounds 3 – 7, 15, and 16 did not significantly stimulate 
adenylyl cyclase in human A2BAR-expressing CHO cells (<10% of the effect of 10 µM NECA, 
as a full agonist). Compounds 2, 8 – 14, 17, 19, and 23 at 10 µM stimulated adenylyl cyclase by 
<50%. Compounds 18 and 31 produced approximately 50% stimulation at 10 µM. Thus, 
selectivity for the A3AR was demonstrated; these nucleosides that activate the A3AR at low nM 
concentrations activated the A2BAR only at substantial µM concentrations.  
 
Based on previous findings, it is predicted that only the analogues containing the substituted N6-
benzyl group (5-chloro-2-methoxy), i.e. full agonist 20 and partial agonist 33, would be expected 
to bind in the nanomolar range to the rat A3AR. Small alkyl groups at the N6 position, such as 
methyl and ethyl, although conducive to high affinity at the human A3AR, led to negligible 
affinity at the rat homologue of the receptor. Selected compounds were measured in binding to 
the rat A3AR expressed in CHO cell membranes using [125I]I-AB-MECA. The Ki values 
determined were as follows: compounds 5, 7, and 8, Ki > 10 µM; compound 9, Ki  = 1.79 µM; 
compound 10, Ki  = 0.312 µM. 
 
Molecular modeling. To explain the structural basis for the high binding affinity of the 
nucleoside 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine 
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10 at hA3AR, we performed a computational study of ligand docking in a previously derived 
A3AR model based on the high resolution structure of bovine rhodopsin.37,38 Various bound 
conformations of the C2-substituent and χ1 angles for the adenine ring were generated for an 
energetically favorable binding location and orientation, and the resulting conformations were 
compared energetically in the putative binding site.  
 
The result of docking 10 in the putative binding site of the A3AR is shown in Figure 1A. The 
purine ring was surrounded by a hydrophobic pocket, defined by L91 (3.33) and L246 (6.51).  In 
addition, the H-bonds formed between the exocyclic amine and the hydroxyl group of S247 
(6.52) and between the purine N1 atom and the side chain of N250 (6.55). The 2-OH group of the 
ribose moiety formed a H-bond with the side chain of Q167 (EL2), and the 3-OH group formed 
an intramolecular H-bond with the 5-OH group. Unlike the previously reported docking models 
of N6-substituted adenosines,37 here the 5-OH group H-bonded with the side chain of H272 
(7.43) and the backbone carbonyl group of S271 (7.42). The cyclopentyl moiety interacted with 
aliphatic hydrophobic residues, M177 (5.38) and V178 (5.39), through a hydrophobic interaction 
and were situated in proximity to F168 (EL2) F182 (5.43), consistent with the optimized binding 
affinity of compound 10.  
 
A comparison of the docking modes of Cl-IB-MECA and compound 10 in the putative binding 
domain showed considerable overlap of the ribose rings and of the adenine moieties, although in 
compound 10 both were situated a little closer to extracellular loop 2 (Figure 1B). Previously, it 
was noted that 5-uronamide analogues, typically of derivatives having bulky N6-subsitituents, 
generally gain affinity in comparison to the corresponding 5-hydroxyl analogue. Here, the 5-
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uronamide analogue 19 (agonist) of the most potent 5-hydroxyl analogue 10 (antagonist) 
displayed a lower binding affinity, which could be explained by the shift of the ribose position in 
adenosine analogue having a bulky 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl) substituent in 
comparison to those having N6 bulky substituents. The binding of the cyclopentylmethyl group in 
10 was directed more toward the upper part of TM5, partially overlapping with the binding site of 
the 3-iodophenyl ring in Cl-IB-MECA. Curiously, other closely related triazolo derivatives 
displayed a higher potency of the 5-uronamide analogues, thus the compound 10 must bind to 
the receptor in a very distinct manner. There was a subtle difference in orientation between the 2-
cyclopentyl group and bulkier groups like benzyl (9) or cyclohexylmethyl (11), which were 
associated with unfavorable van der Waals interactions and resulting in a decrease of binding 
affinity of 7- and 16-fold, respectively. In addition, the same preferred χ1 angles of the 
energetically favorable bound conformation, common to Cl-IB-MECA and compound 10, was 
consistent with the empirical finding that the combination of bulky N6 and C2 substituents was 
unfavorable for A3AR selectivity because of competitive interaction of these bulky substituents. 
Thus, the modeling has demonstrated the human A3AR preference of 2-(4-cyclopentylmethyl-
1,2,3-triazol-1-yl) derivatives in the 5-OH series might be explained by optimal van der Waals 
interactions. 
 
Conclusions 
Several 2-(1,2,3-triazol-1-yl)-N6-methyl-substituted adenosine derivatives described in the 
present study displayed A3AR affinities in the low nanomolar range, showed very high A3/A2A 
and a moderate to high A3/A1 selectivity. Contrary to what we expected, the 2-triazole analogues 
with an unmodified ribose moiety (1-14) showed antagonist or weak partial agonist activity at the 
V178 
C251 
M172 
N250 
S247 
A 
N250 
A 
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A3AR. A 2-(4-cyclopentylmethyl-(1,2,3-triazol-1-yl))-N6-methyl derivative 10 was 260-fold 
selective in binding in comparison to the A1AR. The binding of the 4-cyclopentylmethyl group in 
10, in distinction to the binding of closely related bulky groups pendant on the triazole ring, was 
directed more toward the upper part of TM5 partially overlapping with the binding site of the 3-
iodophenyl ring in Cl-IB-MECA. The 5-N-ethyluronamide modification was dominant over the 
efficacy reducing effects at the 2 position and was capable of fully re-establishing the A3AR 
agonist activity, resulting in highly potent and selective A3AR agonists 15-19. The most selective 
agonist derivative was compound 17, 9-(5-ethylcarbamoyl--D-ribofuranosyl)-N6-methyl-2-(4-
pyridin-2-yl-1,2,3-triazol-1-yl)adenine, which was 910-fold selective in binding to the A3AR in 
comparison to the A1AR. The retention of high human A3AR affinity in compound 20 was not 
typical of previous findings that double bulky substitution at the 2 and N6 positions tended to 
reduce A3AR affinity markedly. Thus, the 2-triazol-1-yl N6-methyl adenosine analogues 1-11 
constitute a novel class of highly potent and selective nucleoside-based A3AR partial agonists and 
antagonists, all of which maintain an intact ribose in the molecular structure, and agonists. Since 
the reported analogues show excellent affinity for the A3AR and span the full intrinsic activity 
range, they might be useful as pharmacological tools or as leads for further optimisation. 
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Experimental section 
All reagents were from standard commercial sources and of analytic grade, except for the 
benzylic azides, which were prepared by treating the corresponding benzylic bromides with NaN3 
in DMF. Precoated Merck silica gel F254 plates were used for TLC, and spots were examined 
under UV light at 254 nm and further visualized by sulphuric acid-anisaldehyde spray.  Column 
chromatography was performed on ICN silica gel (63-200 µm, 60Å, ICN Biochemicals, 
Eschwege, Germany). NMR spectra were obtained with a Varian Mercury 300 MHz 
spectrometer.  Chemical shifts are given in ppm () relative to the residual solvent signals, which 
in the case of DMSO-d6 were 2.54 ppm for 1H and 40.5 ppm for 13C. Structural assignment was 
confirmed with COSY and DEPT.  All signals assigned to hydroxyl groups were exchangeable 
with D2O. Exact mass measurements were performed on a quadrupole/orthogonal-acceleration 
time-of-flight (Q/oaTOF) tandem mass spectrometer (qToF 2, Micromass, Manchester, UK) 
equipped with a standard electrospray ionization (ESI) interface.  Samples were infused in a 2-
propanol/water (1:1) mixture at 3 µL/min. For the compounds that precipitated from the reaction 
medium, the yields were calculated from the amount obtained after filtration, and are lower than 
the actual yields, since in most cases a considerable amount remained in solution. 
N6-Methyl-9-(-D-ribofuranosyl)-2-(1,2,3-triazol-1-yl)adenine (1). In a pressure tube was 
added 23 (165 mg, 0.51 mmol) trimethylsilylacetylene (292 µL, 2.05 mmol) and 4 mL DMF. The 
mixture was stirred at 105 °C for 15h. After solvent evaporation, the yellowish residue was 
dissolved in 2 mL of a 1.0 M solution of tetrabutylammonium fluoride in THF and stirred for 5h. 
The reaction was monitored by NMR After evaporation of the solvent, the residue was dissolved 
in ethyl acetate. Water was added and the triazole product precipitated in the water layer. After 
overnight cooling and filtration, the precipitate was further purified on a silica gel column 
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(CH2Cl2:MeOH 92:8) and yielded compound 1 as a white solid (82 mg, 46 %). 1H NMR (300 
MHz, DMSO-d6):  3.06 (d, 3H, J = 4.5 Hz, N6-CH3), 3.54-3.61 (m, 1H, H-5’A), 3.65-3.72 (m, 
1H, H-5’B), 3.96 (dd, 1H, J = 3.8 and 7.9 Hz, H-4’), 4.20 (dd, 1H, J = 4.7 and 8.2 Hz, H-3’), 4.65 
(app q, J = 5.9 Hz, H-2’), 4.98 (t, 1H, J = 5.6 Hz, 5’-OH), 5.23 (d, 1H, J = 5.0 Hz, 3’-OH), 5.48 
(d, 1H, J = 6.2 Hz, 2’-OH), 5.95 (d, 1H, J = 5.9 Hz, H-1’), 7.92 (d, 1H, J = 1.2 Hz, H 4”), 8.37 (d, 
1H, J = 4.6 Hz, N6-H), 8.46 (s, 1H, H-8), 8.82 (br s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6): 
 27.84 (N6-CH3), 62.19 (C-5’), 71.13 (C-3’), 74.30 (C-2’), 86.42 (C-4’), 88.01 (C-1’), 119.75 
(C-5), 124.67 (C-5”), 134.25 (C-4”), 141.13 (C-8), 149.56 and 149.85 (C-2 and C-4), 156.082 (C-
6); HRMS (ESI-MS) C13H17N8O4: [M+H]+: 349.1367  found; 349.1372 calcd. Anal. 
(C13H16N8O4.1/2H2O) C, H, N. 
2-(4-Ethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine (2). Compound 23 (70 
mg, 0.217 mmol), sodium ascorbate (8.6 mg, 0.043 mmol) and CuSO4.5H2O (2.2 mg, 0.009 mmol) 
were suspended in 20 mL H2O:tBuOH (3:1). The mixture was saturated with 1-butyne and stirred 
for 4 d at room temperature in a parr apparatus. Purification on a preparative silica gel TLC 
(CH2Cl2:MeOH 90:10) resulted in compound 2 as a white solid in 40% yield. 1H NMR (300 
MHz, DMSO-d6):  1.27 (t, 3H, J = 7.62 Hz, CH3), 2.75 (q, 2H, J = 7.6 Hz, CH2), 3.05 (d, 3H, J 
= 4.4 Hz, N6-CH3), 3.51-3.59 (m, 1H, H-5’A), 3.61-3.70 (m, 1H, H-5’B), 3.94 (dd, 1H, J = 4.0 en 
7.6 Hz, H-4’), 4.15 (dd, 1H, J = 4.4 and 7.9 Hz, H-3’), 4.60 (app q,  J = 5.6 Hz, H-2’), 4.97 (t, 
1H, J = 5.6 Hz, 5’-OH), 5.22 (d, 1H, J = 4.7 Hz, 3’-OH), 5.47 (d, 1H, J = 6.2 Hz, 2’-OH), 5.93 
(d, 1H, J = 6.2 Hz, H-1’), 8.34 (d, 1H, J =  4.4 Hz, N6-H), 8.45 (s, 1H, H-8), 8.55 (s, 1H, H-5”); 
13C NMR (300 MHz, DMSO-d6) ):  14.32 (CH3), 19.08 (CH2), 27.84 (N6-CH3), 62.13 (C-5’), 
71.15 (C-3’), 74.34 (C-2’), 86.43 (C-4’), 87.84 (C-1’), 119.57 (C-5), 120.962 (C-5’’), 140.92 (C-
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8), 149.31, 149.63, 149.88 (C-2, C4 and C-4”), 156.05 (C-6); HRMS (ESI-MS) C15H21N8O4 
[M+H]+: 377.1682 found; 377.1685 calcd. Anal. (C15H20N8O4) C, H, N.  
General procedure for the synthesis of 4”-substituted 2-(1,2,3-triazol-1-yl)adenosine 
derivatives 3-11. Compound 23 (70 mg, 0.217 mmol), sodium ascorbate (8.6 mg, 0.043 mmol) 
and CuSO4.5H2O (2.2 mg, 0.009 mmol) were suspended in 2 mL H2O:tBuOH (3:1).  The 
appropriate alkyne (2 equiv.) was subsequently added and the mixture was stirred overnight at 
room temperature.  The 2-triazol-1-yl compounds (generally) precipitated from this reaction 
medium and were isolated by filtration with water. 
2-(4-Butyl-1,2,3-triazol-1-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine (3).The reaction of 23 
(70 mg, 0.217 mmol) with 1-hexyne (50 µL, 0.435 mmol) gave compound 3 in 59% yield. 1H 
NMR (300 MHz, DMSO-d6):  0.93 (t, 3H, J = 7.3 Hz, CH3), 1.38 (m, 2H, CH2), 1.66 (m, 2H, 
CH2), 2.71 (t, 2H, J = 7.2 Hz, C4’’-CH2), 3.05 (d, 3H, J = 4.0 Hz, N6-CH3), 3.52-3.62 (m, 1H, H-
5’A), 3.62-3.72 (m, 1H, H-5’B), 3.95 (dd, 1H, J = 3.6 and 7.2 Hz, H-4’), 4.18 (dd, 1H, J = 4.8 
and 8.1 Hz, H-3’), 4.62 (app q, 1H, J = 5.7 Hz, H-2’), 5.01 (t, 1H, J = 5.2 Hz, 5’-OH), 5.29 (d, 
1H, J = 4.0 Hz, 3’-OH), 5.54 (d, 1H, J = 5.6 Hz, 2’-OH), 5.94 (d, 1H, J = 5.9 Hz, H-1’), 8.36 (d, 
1H, J = 4.1 Hz, N6-H), 8.45 (s, 1H, H-8), 8.56 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6):  
14.37 (CH3), 22.37 (CH2), 25.21 (CH2), 27.83 (N6-CH3), 31.68 (CH2), 62.14 (C-5’), 71.15 (C-3’), 
74.36 (C-2’), 86.43 (C-4’), 87.88 (C-1’), 119.56 (C-5), 121.33 (C-5”), 140.96 (C-8), 147.88 and 
149.90 (C-2, C-4 and C4”), 156.07 (C-6); HRMS (ESI-MS) C17H25N8O4 [M+H]+: 405.1992 
found, 405.1998 calcd. Anal. (C17H24N8O4) C, H, N. 
2-[4-(2-Hydroxyethyl)-1,2,3-triazol-1-yl]-N6-methyl-9-(-D-ribofuranosyl)adenine (4). The 
reaction of 23 (70 mg, 0.217 mmol) with 3-butyn-1-ol (33 µL, 0.435 mmol) afforded compound 
4 without precipitation. After solvent evaporation, the mixture was purified on a silica gel column 
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(CH2Cl2:MeOH 90:10 + 1% 7N NH3 in MeOH) yielding compound 11 as a white solid in 68% 
yield. 1H NMR (300 MHz, DMSO-d6):  2.85 (t, 2H, J = 6.9 Hz, CH2), 3.03 (d, 3H, J = 4.7 Hz, 
N6-CH3), 3.52-3.59 (m, 1H, H-5’A), 3.63-3.72 (m, 3H, H-5’B and CH2), 3.94 (dd, 1H, J = 3.5 
and 7.3 Hz, H-4’), 4.16 (dd, 1H, J = 4.8 and 8.1 Hz, H-3’), 4.59 (app q, 1H, J = 5.4 Hz, H-2’), 
4.74 (t, 1H, J = 5.8 Hz, CH2-OH), 4.97 (app t, 1H, J = 5.6 Hz, 5’-OH), 5.24 (d, 1H, J = 5.0 Hz, 
3’-OH), 5.50 (d, 1H, J = 6.2 Hz, 2’-OH), 5.93 (d, 1H, J = 6.2 Hz, H-1’), 8.31 (d, 1H, J = 4.7 Hz, 
N6-H), 8.43 (s, 1H, H-8), 8.54 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6):  27.83 (N6-CH3), 
29.70 (CH2), 60.85 (CH2-OH), 62.13 (C-5’), 71.15 (C-3’), 74.35 (C-2’), 86.43 (C-4’) 87.81 (C-
1’), 119.56 (C-5), 122.02 (C-5”), 140.49 (C-8), 145.49, 149.88 and 149.65 (C-2, C-4 and C4”), 
156.05 (C-6); HRMS (ESI-MS) C15H21N8O5 [M+H]+: 393.1630 found, 393.1634 calcd. Anal. 
(C15H20N8O5.H2O) C, H, N. 
2-(4-Dimethylaminomethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine (5). 
The reaction of 23 (70 mg, 0.217 mmol) with 1-dimethylamino-2-propyne (47 µL, 0.435 mmol) 
gave compound 5 without precipitation. The volatiles were removed under reduced pressure, and 
the residue purified on a silica gel column (CH2Cl2:MeOH 80:10 + 1% 7N NH3 in MeOH). 
Compound 5 was obtained as a white solid in 67% yield. 1H NMR (300 MHz, DMSO-d6):  2.20 
(s, 6H, 2 x CH3), 3.05 (d, 3H, J = 4.4 Hz, N6-CH3), 3.54-3.62 (m, 3H, H-5’A and CH2), 3.65-3.72 
(m, 1H, H-5’B), 3.95 (dd, 1H, J = 4.1 and 7.6 Hz, H-4’), 4.18 (dd, 1H, J = 5.0 and 8.2 Hz, H-3’), 
4.62 (app q, 1H, J = 5.4 Hz, H-2’), 4.98 (t, 1H, J = 5.6 Hz, 5’-OH), 5.23 (d, 1H, J = 5.0 Hz, 3’-
OH), 5.49 (d, 1H, J = 6.2 Hz, 2’-OH), 5.95 (d, 1H, J = 6.2 Hz, H-1’), 8.38 (d, 1H, J = 4.4 Hz, N6-
H), 8.45 (s, 1H, H-8), 8.64 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6) ):  27.85 (N6-CH3), 
45.18 (N(CH3)2), 53.85 (CH2), 62.10 (C-5’), 71.12 (C-3’), 74.38 (C-2’), 86.41 (C-4’), 87.84 (C-
1’), 119.64 (C-5), 123.328 (C-5’’), 140.97 (C-8), 144.41, 149.59, 149.79 (C-2, C4 and C-4”), 
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156.05 (C-6); HRMS (ESI-MS) C16H24N9O4 [M+H]+: 406.1944 found,  406.1951 calcd. Anal. 
(C16H23N9O4) C, H, N; N calcd, 31.09; found, 30.41. 
N6-Methyl-2-(4-phenyl-1,2,3-triazol-1-yl)-9-(-D-ribofuranosyl)adenine (6). The reaction of 
23 (70 mg, 0.217 mmol) with phenylacetylene (48 µL, 0.435 mmol) yielded compound 6 (54%) 
as a white solid. 1H NMR (300 MHz, DMSO-d6):  3.11 (d, 3H, J = 4.5 Hz, N6-CH3), 3.55- 3.63 
(m, 1H, H-5’A), 3.67-3.74 (m, 1H, H-5’B), 3.97 (dd, J = 3.6 and 7.2 Hz, H-4’), 4.21 (dd, J = 4.8 
and 8.1 Hz, H-3’), 4.66 (app q, J = 5.4 Hz, H-2’), 5.03 (app t, 1H, J = 5.6 Hz, 5’-OH), 5.29 (d, 
1H, J = 5.0 Hz, 3’-OH), 5.54 (d, 1H, J = 6.2 Hz, 2’-OH), 5.99 (d, 1H, J = 5.9 Hz, H-1’), 7.4 (t, 
1H, J = 7.3 Hz, Ph), 7.50 (t, 2H, J = 7.5 Hz, Ph), 8.06 (d, 2H, J = 7.3 Hz, Ph), 8.44 (d, 1H, J = 4.5 
Hz, N6-H), 8.49 (s, 1H, H-8), 9.31 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6):  27.92 (N6-
CH3), 62.16 (C-5’), 71.17 (C-3’), 74,39 (C-2’), 86.48 (C-4’), 87.94 (C-1’), 119.85 (C-5), 120.68 
(C-5”), 126.27, 128.95, 129.61 and 130.85 (Ph), 141.082 (C-8), 147.02 and 149.77 (C-2, C-4 and 
C-4”), 156.10 (C-6); HRMS (ESI-MS) C19H21N8O4 [M+H]+: 425.1689 found,  425.1685 calcd. 
Anal. (C19H20N8O4) C, H, N. 
N6-Methyl-2-[4-pyridin-2-yl-1,2,3-triazol-1-yl]-9-(-D-ribofuranosyl)adenine (7). The 
reaction of 23 (70 mg, 0.217 mmol) with 2-ethynylpyridine (44 µL, 0.435 mmol) afforded 
compound 7 as a white solid in 55% yield. 1H NMR (300 MHz, DMSO-d6):  3.09 (d, 3H, J = 
4.1 Hz, N6-CH3), 3.57-3.66 (m, 1H, H-5’A), 3.67-3.76 (m, 1H, H-5’B), 3.97 (dd, 1H, J = 3.9 and 
7.5 Hz, H-4’), 4.19 (dd, 1H, J = 4.8 and 8.1 Hz, H-3’), 4.64 (app q, 1H, J = 6.0 Hz, H-2’), 4.99 (t, 
1H, J = 5.6 Hz, 5’-OH), 5.26 (d, 1H, J = 5.0 Hz, 3’-OH), 5.54 (d, 1H, J = 6.2 Hz, 2’-OH), 5.99 
(d, 1H, J = 5.9 Hz, H-1’), 7.42 (m, 1H, pyridin-2-yl) , 7.96 (m, 1H, pyridin-2-yl), 8.16 (d, 1H, J = 
7.3 Hz, pyridin-2-yl), 8.42 (d, 1H, J = 4.1 Hz, 1H, N6-H), 8.49 (s, 1H, H-8), 8.68 (d, 1H, J = 4.1 
Hz, pyridin-2-yl), 9.16 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6):  27.92 (N6-CH3), 62.13 
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(C-5’), 71.14 (C-3’), 74.49 (C-2’), 86.47 (C-4’), 88.16 (C-1’), 119.92 (C-5), 120.53 (C-5’’), 
121.07 (pyridin-2-yl), 122.25 (pyridin-2-yl), 137.79 (pyridin-2-yl), 141.28 (C-8), 148.47, 150.45 
and 150.56 (C-2, C-4, C-4”and pyridin-2-yl), 156.28 (C-6); HRMS (ESI-MS) C18H19N9O4Na 
[M+Na]+: 448.1458 found,  448.1457 calcd. Anal. (C18H19N9O4) C, H, N. 
N6-Methyl-2-[4-(4-propoxyphenyl)-1,2,3-triazol-1-yl]-9-(-D-ribofuranosyl)adenine (8). The 
reaction of 23 (70 mg, 0.217 mmol) with 1-eth-1-ynyl-4-propoxybenzene (57 µL, 0.435 mmol) 
afforded compound 8 as a white solid in 36% yield. 1H NMR (300 MHz, DMSO-d6):  0.99 (t, 
3H, J = 7.3 Hz, CH3), 1.71-1.78 (m, 2H, CH2), 3.10 (d, 3H, J = 4.1 Hz, N6-CH3), 3.54-3.62 (m, 
1H, H-5’A), 3.64-3.72 (m, 1H, H-5’B), 3.98 (m, 3H, H-4’and CH2), 4.18 (dd, 1H, J = 4.8 and 8.1 
Hz, H-3’), 4.64 (app q, 1H, J = 5.4 Hz, H-2’), 4.99 (t, 1H, J = 5, 7 Hz, 5’-OH), 5.25 (d, 1H, J = 
4.1 Hz, 3’-OH), 5.50 (d, 1H, J = 5.9 Hz, 2’-OH), 5.97 (d, 1H, J = 6.2 Hz, H-1’), 7.03 (d, 2H, J = 
8.8 Hz, Ph), 7.94 (d, 2H, J = 8.8 Hz, Ph), 8.36 (d, 1H, J = 4.1 Hz, 1H, N6-H), 8.45 (s, 1H, H-8), 
9.15 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6):  11.08 (CH3), 22.73 (CH2), 27.90 (N6-
CH3), 62.16 (C-5’), 69.71 (OCH2), 71.18 (C-3’), 74.38 (C-2’), 86.46 (C-4’), 87.91 (C-1’), 115.50 
(Ph), 119.60 (C-5), 123.28 (C-5’’), 127.66 (Ph), 140.01 (C-8), 147.01, 149.82, 150.45 (C-4, C-2 
and C-4”), 156.10 (C-6); HRMS (ESI-MS) C22H27N8O5 [M+H]+: 483.2109 found,  483.2104 
calcd. Anal. (C22H26N8O5) C, H, N. 
N6-Methyl-2-(4-benzyl-1,2,3-triazol-1-yl)-9-(-D-ribofuranosyl)adenine (9). The reaction of 
23 (70 mg, 0.217 mmol) with 3-phenyl-1-propyne (54 µL, 0.435 mmol) gave compound 9 as a 
white solid in 43% yield. 1H NMR (300 MHz, DMSO-d6):  3.03 (d, 3H, J = 3.8 Hz, N6-CH3), 
3.53-3.62 (m, 1H, H-5’A), 3.64-3.71 (m, 1H, H-5’B), 3.95 (dd, 1H, J = 3.7 and 7.2 Hz, H-4’), 
4.11 (s, 2H, CH2), 4.17 (dd, 1H, J = 4.8 and 8.1 Hz, H-3’), 4.61 (app q, 1H, J = 5.7 Hz, H-2’), 
4.97 (app t, 1H, J = 5.3 Hz, 5’-OH), 5.22 (d, 1H, J = 4.7 Hz, 3’-OH), 5.47 (d, 1H, J = 5.9 Hz, 2’-
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OH), 5.94 (d, 1H, J = 5.9 Hz, H-1’), 7.23 (m, 1H, Ph), 7.32 (d, 4H, J = 4.4 Hz, Ph), 8.34 (d, 1H, J 
= 3.8 Hz, N6-H), 8.45 (s, 1H, H-8), 8.59 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6):  25.32 
(N6-CH3), 32.51 (CH2), 62.11 (C-5’), 71.13 (C-3’), 74.43 (C-2’), 86.41 (C-4’), 87.96 (C-1’), 
121.42 (C-5), 121.97 (C-5”), 126.91, 129.12, 129.21 and 140.02 (Ph), 140.88 (C-8), 147.42, 
149.58 and 149.81 (C-4, C-2 and C-4”), 156.09 (C-6); HRMS (ESI-MS) C20H23N8O4 [M+H]+: 
439.1846 found, 439.1842 calcd. Anal. (C20H22N8O4) C, H, N.  
2-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine (10). 
The reaction of 23 (70 mg, 0.217 mmol) with 3-cyclopentyl-1-propyne (57 µL, 0.435 mmol) 
yielded compound 10 (32%) as a white solid. 1H NMR (300 MHz, DMSO-d6):  1.23-1.28 (m, 
2H, cyclopentyl), 1.48-1.62 (m, 4H, cyclopentyl), 1.71-1.75 (m, 2H, cyclopentyl), 2.19-2.25 (m, 
1H, cyclopentyl), 2.72 (d, 2H, J = 7.3 Hz, CH2-cyclopentyl), 3.05 (d, 3H, J = 3.9 Hz, N6-CH3), 
3.53-3.61 (m, 1H, H-5’A), 3.63-3.72 (m, 1H, H-5’B), 3.96 (dd, 1H, J = 3.6 and 7.2 Hz, H-4’), 
4.19 (dd, 1H, J = 4.8 and 8.1 Hz, H-3’), 4.62 (app q, 1H, J = 5.9 Hz, H-2’), 4.98 (t, 1H, J = 5.3 
Hz, 5’-OH), 5.23 (d, 1H, J = 4.7 Hz, 3’-OH), 5.49 (d, 1H, J = 6.5 Hz, 2’-OH), 5.95 (d, 1H, J = 
5.9 Hz, H-1’), 8.34 (d, 1H, J = 3.9 Hz, N6-H), 8.45 (s, 1H, H-8), 8.55 (s, 1H, H-5”); 13C NMR 
(300 MHz, DMSO-d6):  25.37 (cyclopentyl), 27.83 (N6-CH3), 31.56 (CH2), 32.55 (cyclopentyl), 
62.15 (C-5’), 71.15 (C-3’), 74.34 (C-2’), 86.43 (C-4’), 87.87 (C-1’), 119.60 (C-5), 121.58 (C-5”), 
140.92 (C-8), 147.33, 149.89 (C-4, C-2 and C4”), 156.07 (C-6); HRMS (ESI-MS) C19H27N8O4 
[M+H]+: 431.2153 found, 431.2155 calcd. Anal. (C19H26N8O4) C, H, N. 
2-(4-Cyclohexylmethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine (11). The 
reaction of 23 (70 mg, 0.217 mmol) with cyclohexyl-1-propyne (63 µL, 0.435 mmol) gave 
compound 11 in 82 % yield. 1H NMR (300 MHz, DMSO-d6):  0.86-1.28 (br m, 6H, cyclohexyl), 
1.54-1.72 ( br m, 5H, cylcohexyl), 2.58 (d, 2H, J = 6.9 Hz, CH2), 3.03 (d, 3H, J = 3.9 Hz, N6-
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CH3), 3.51-3.59 (m, 1H, H-5’A), 3.63-3.70 (m, 1H, H-5’B), 3.94 (dd, 1H, J =  4.2 and 7.5 Hz, H-
4’),  4.16 (dd, 1H, J =  4.8 and 8.1 Hz, H-3’), 4.59 (app q, 1H, J = 6.3 Hz, H-2’), 4.97 (t, 1H, J = 
5.5 Hz, 5’-OH), 5.22 (d, 1H, J = 4.8 Hz, 3’-OH), 5.47 (d, 1H, J = 6.3 Hz, 2’-OH), 5.93 (d, 1H, J 
=  6.0 Hz, H-1’), 8.30 (d, 1H, J = 3.9 Hz, N6-H), 8.43 (s, 1H, H-8), 8.51 (s, 1H, H-5”);13C NMR 
(300 MHz, DMSO-d6):  26.31 (cyclohexyl), 26.66 (cyclohexyl), 27.84 (N6-CH3), 33.16 
(cyclohexyl), 38.22 (CH2), 62.14 (C-5’), 71.15 (C-3’), 74.35 (C-2’), 86.44 (C-4’), 87.86 (C-1’), 
119.60 (C-5), 121.93 (C-5”), 140.92 (C-8), 146.45, 149.92 (C-4, C-2 and C-4”), 153.51 (C-6); 
HRMS (ESI-MS) C20H29N8O4 [M+H]+: 445.2305 found, 445.2311 calcd. Anal. (C20H28N8O4) C, 
H, N. 
General procedure for the synthesis of 4”-substituted 2-(1,2,3-triazol-4-yl)adenosine 
derivatives 12-14. Compound 25 (100 mg, 0.32 mmol), sodium ascorbate (13 mg, 0.06 mmol 
mmol) and CuSO4.5H2O (3 mg, 0. 013 mmol) were suspended in 30 mL H2O:tBuOH (3:1).  The 
appropriate azide (2 equiv.) was subsequently added and the mixture was stirred overnight at 
room temperature.  The 2-triazol-4-yl compounds (generally) precipitated from this reaction 
medium and were isolated by filtration with water. 
2-(1-Benzyl-1,2,3-triazol-4-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine (12). The reaction of 
25 (100 mg, 0.32 mmol) with 85 mg (0.64 mmol) benzylazide gave compound 12 in 78 % yield 
(110 mg). 1H NMR (300 MHz, DMSO-d6):  3.03 (br s, 3H, N6-CH3), 3.52-3.58 (m, 1H, H-5’A), 
3.60-3.66 (m, 1H, H-5’B), 3.92 (app d, H-4’, J = 2.9 Hz, H-4’), 4.15 (dd, 1H, J = 4.7 and 7.6 Hz, 
H-3’), 4.60 (app q, 1H, J = 5.9 Hz, H-2’), 5.08 (t, 1H, J = 5.4 Hz, 5’-OH), 5.19 (d, 1H, J = 3.5 
Hz, 3’-OH), 5.44 (d, 1H, J = 5.6 Hz, 2’-OH), 5.68 (s, 2H, CH2), 5.97 (d, 6.2 Hz, H-1’), 7.38 (br s, 
5H, Ph), 7.82 (br s, 1H, N6-H), 8.36 (s, 1H, H-8), 8.66 (s, 1H, H-5”);13C NMR (300 MHz, 
DMSO-d6): δ 27.54 (N6-CH3), 53.62 (CH2), 62.29 (C-5’), 71.30 (C-3’), 74.30 (C-2’), 86.41 (C-
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4’), 87.77 (C-1’), 119.52 (C-5), 126.41 (C-5”), 128.63, 128.86, 129.48 and 136.71 (Ph), 140.27 
(C-8), 148.22, 153.56, 153.72 (C-2, C-4 and C-4’), 155.69 (C-6); HRMS (ESI-MS) C20H23N8O4  
[M+H]+: 439.1834 found, 439.1842 calcd. Anal. (C20H22N8O4) C, H, N. 
2-[1-(3-Methoxybenzyl)-1,2,3-triazol-4-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine (13). 
The reaction of 25 (100 mg, 0.32 mmol) with 104 mg (0.64 mmol) 3-methoxybenzylazide gave 
compound 13 in 80 % yield (120 mg). 1H NMR (300 MHz, DMSO-d6):  3.03 (br s, 3H, N6-
CH3), 3.52-3.60 (m, 1H, H-5’A), 3.64-3.72 (m, 1H, H-5’B), 3.95 (app d, H-4’, J = 2.9 Hz, H-4’), 
4.15 (dd, 1H, J = 4.7 and 7.6 Hz, H-3’), 4.60 (app q, 1H, J = 6.4 Hz, H-2’), 5.07 (t, 1H, J = 5.1 
Hz, 5’-OH), 5.21 (d, 1H, J = 4.2 Hz, 3’-OH), 5.46 (d, 1H, J = 6.3 Hz, 2’-OH), 5.62 (s, 2H, CH2), 
5.95 (d, 1H, J = 6.6 Hz, H-1’), 6.91 (m, 3H, Ph), 7.29 (t, 1H, J = 7.9 Hz, Ph), 7.79 (br s, 1H, N6-
H), 8.34 (s, 1H, H-8), 8.63 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6): δ 27.59 (N6-CH3), 
53.45 (CH2), 55.82 (OCH3), 62.30 (C-5’), 71.33 (C-3’), 74.25 (C-2’), 86.42 (C-4’), 87.70 (C-1’), 
114.44 and 114.20 (Ph), 119.51 (C-5), 120.72 (Ph), 130.65 (C-5”), 138.21 (C-8), 148.22, 153.56, 
153.64 (C-2, C-4 and C-4’), 155.69 (C-6), 160.14 (Ph); HRMS (ESI-MS) C21H25N8O5  [M+H]+: 
469.1938 found, 469.1947 calcd. Anal. (C21H24N8O5) C, H, N. 
2-[1-(3-Chlorobenzyl)-1,2,3-triazol-4-yl)-N6-methyl-9-(-D-ribofuranosyl)adenine (14). The 
reaction of 25 (100 mg, 0.32 mmol) with 107 mg (0.64 mmol) 3-chlorobenzylazide gave 
compound 14 in 73 % yield (110 mg). 1H NMR (300 MHz, DMSO-d6):  3.04 (br s, 3H, N6-
CH3), 3.53-3.60 (m, 1H, H-5’A), 3.64-3.71 (m, 1H, H-5’B), 3.96 (app d, H-4’, J = 2.9 Hz, H-4’), 
4.17 (dd, 1H, J = 4.7 and 7.6 Hz, H-3’), 4.64 (app q, 1H, J = 5.8 Hz, H-2’), 5.09 (t, 1H, J = 5.3 
Hz, 5’-OH), 5.20 (d, 1H, J = 4.4 Hz, 3’-OH), 5.45 (d, 1H, J = 6.2 Hz, 2’-OH), 5.97 (d, 1H, J = 
6.2 Hz, H-1’), 7.31-7.36 (m, 1H, Ph), 4.41-7.47 (m, 3H, Ph), 7.83 (br s, 1H, N6-H), 8.37 (s, 1H, 
H-8), 8.72 (s, 1H, H-5”);13C NMR (300 MHz, DMSO-d6): δ 27.54 (N6-CH3), 52.80 (CH2), 62.31 
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(C-5’), 71.33 (C-3’), 74.27 (C-2’), 86.43 (C-4’), 87.69 (C-1’), 119.56 (C-5), 126.63 (C-5”), 
127.53, 128.53, 128.84, 131.42, 133.98 and 139.15 (Ph), 140.36 (C-8), 148.22, 150.03 and 
153.43 (C-2, C-4 and C-4’), 155.78 (C-6); HRMS (ESI-MS) C20H22N8O4Cl  [M+H]+: 473.1452 
found, 473.1452 calcd. Anal. (C20H21N8O4Cl) C, H, N. 
9-(5-Ethylcarbamoyl--D-ribofuranosyl)-N6-methyl-2-(1,2,3-triazol-1-yl)adenine (15) 
In a pressure tube was added 31 (110 mg, 0.30 mmol) trimethylsilylacetylene (259 µL, 1.81 
mmol) and 4 mL DMF. The mixture was stirred at 105 °C for 15h. Solvent evaporation yielded a 
yellowish solid that was dissolved 6 mL of a 1.0 solution of tetrabutylammonium fluoride in THF 
and stirred for 5 h. After solvent evaporation, the residue was dissolved in ethyl acetate. Water 
was added and the triazole precipitated in the water layer. After overnight cooling and filtration, 
the precipitate was further purified on a silica gel column (CH2Cl2:MeOH 93:7) and yielded 
compound 15 as a white solid (49 mg, 42 %). 1H NMR (300 MHz, DMSO-d6):  0.90 (t, 3H, 
CH3), 3.05-3.21 (m, 2H, N-CH2), 3.05 (d, 3H, J = 4.2 Hz, N6-CH3), 4.26 (m, 1H, H-3’), 4.33 (d, 
1H, J = 2.1 Hz, H-4’), 5.61 (d, 1H, J = 6.2 Hz, 3’-OH), 5.71 (d, 1H, J = 4.7 Hz, 2’-OH), 6.04 ( d, 
1H, J = 7.2 Hz, H-1’), 7.91 (d, 1H, J = 1.2 Hz, H-4”), 8.07 (t, 1H, J = 5.3 Hz, NHCO), 8.41 (d, 
1H, J = 4.2 Hz, N6-H), 8.54 (s, 1H, H-8), 8.82 (br s, 1H, H-5”);13CMR (300 MHz, DMSO-d6):  
15.16 (CH3), 27.85 (N6-CH3), 34.07 (CH2), 73.64 (C-2’ and C-3’), 84.98 (C-4’), 88.02 (C-1’), 
119.91 (C-5), 124.70 (C-5”), 134.29 (C-4”), 141.59 (C-8), 149.69 and 149.90 (C-2 and C-4), 
156.14 (C-6), 169.73 (C=O); HRMS (ESI-MS) C15H20N9O4  [M+H]+: 390.1676 found, 390.1683 
calcd. Anal. (C15H19N9O4) C, H, N. 
General procedure for the synthesis of 4”-substituted 2-(1,2,3-triazol-1-yl) adenosine 
derivatives 16-18. To a mixture of 31 (100 mg, 0.28 mmol), CuI (5 mg, 0.03 mmol) and 
triethylamine (40 µL, 0.28 mmol) in water:acetonitrile (1:1), the appropriate alkyne (2 equiv.) 
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was added. The mixture was stirred for 5 d at room temperature. The reaction was monitored by 
1H-NMR. The product was precipitated with water and cooled overnight. After filtration, the 
yellowish solid was purified on a silica gel column (CH2Cl2: MeOH 90:10) to obtain the 1,2,3-
triazol-1-yl adenosine derivative as a white solid.   
2-(4-Butyl-1,2,3-triazol-1-yl)-9-(5-ethylcarbamoyl--D-ribofuranosyl)-N6-methyladenine 
(16). The reaction of compound 31 (100 mg, 0.28 mmol) with 1-hexyne (64µL, 0.56 mmol) gave 
65 mg (53%) of compound 16 as a white solid. 1H NMR (300 MHz, DMSO-d6)  0.88-0.95 (m, 
6H, 2 x CH3), 1.31-1.43 (m, 2H, CH2), 1.61-1.71 (m, 2H, CH2), 2.72 (t, 2H, J = 7.8 Hz, C4’’-
CH2), 3.05-3.22 (m, 2H, N-CH2), 3.05 (d, 3H, J = 4.1 Hz, N6-CH3), 4.25 (m, 1H, H-3’), 4.33 (d, 
1H, J = 2.1 Hz, H-4’), 4.73 (m, 1H, H-2’), 5.59 (d, 1H, J = 6.3 Hz, 3’-OH), 5.69 (d, 1H, J = 4.5 
Hz, 2’-OH), 6.04 (d, 1H, J = 6.9 Hz, H-1’), 8.09 (t, 1H, J = 5.4 Hz), 8.37 (d, 1H, J = 4.1 Hz, N6-
H), 8.53 (s, 1H, H-8), 8.56 (s, 1H, H-5”); 13NMR (300 MHz, DMSO-d6): 14.36 (CH3), 15.17 
(CH3), 22.35 (CH2), 25.21 (CH2), 27.84 (N6-CH3), 31.70 (CH2), 34.07 (CH2), 73.60 and 73.64 (C-
2’ and C-3’), 84.99 (C-4”), 87.91 ( C-1’), 119.79 (C-5), 121.45 (C-5”), 141.49 (C-8), 147.97, 
149, 72 and 149.93 (C-2, C-4 and C-4”), 156.11 (C-6), 169.73 (C=O); HRMS (ESI-MS) 
C19H28N9O4 [M+H]+: 446.2256 found, 446.2264 calcd. Anal. (C19H27N9O4) C, H, N. 
9-(5-Ethylcarbamoyl--D-ribofuranosyl)-N6-methyl-2-(4-pyridin-2-yl-1,2,3-triazol-1-
yl)adenine (17). The reaction of compound 31 (50 mg, 0.14 mmol) with 2-ethynyl-pyridine (56 
µL, 0.56 mmol) gave 35 mg (54 %) of compound 17 as a white solid. 1H NMR (300 MHz, 
DMSO-d6):  0.93 (t, 3H,  J = 7.2 Hz, CH3), 3.09-3.21 (m, 2H, N-CH2), 3.10 (d, 3H, J = 4.2 Hz, 
N6-CH3), 4.25 (m, 1H, H-3’), 4.35 (d, 1H, J =  2.1 Hz, H-4’), 4.74 (m, 1H, H-2’), 5.68 (d, 1H, J = 
6.6 Hz, 2’-OH), 5.75 (d, 1H, J = 4.5 Hz, 3’-OH), 6.08 (d, 1H, J = 6.6 Hz, H-1’), 7.41 (m, 1H, 
pyridin-2-yl), 7.96 (m, 1H, pyridin-2-yl), 8.10 (t, 1H, J = 6.0 Hz, NHCO), 8.16 (d, 1H, J = 8.1 
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Hz, pyridin-2-yl), 8.48 (d, 1H, J = 4.1 Hz, 1H, N6-H), 8.60 (s, 1H, H-8), 8.67 (d, H, J = 5.1 Hz, 
pyridin-2-yl), 9.17 (s, 1H, H-5”); 13NMR (300 MHz, DMSO-d6):  15.18 (CH3), 27.94 (N6-CH3), 
34.11 (N-CH2), 73.69 and 73.78 (C-2’ and C-3’), 84.95 (C-4’), 87.98 (C-1’), 120.04 (C-5), 
120.65 (C-5”), 122.20 and 124.11 (pyridin-2-yl), 138.027 (pyridin-2-yl), 141.64 (C-8), 147.95, 
149,64, 149.67 and 149.98 (C-2, C-4, C-4” and pyridin-2-yl), 150.49 (pyridin-2-yl), 156.13 (C-
6), 169.76 (C=O); HRMS (ESI-MS) C20H23N10O4 [M+H]+: 467.1899 found, 467.1903 calcd. 
Anal. (C20H22N10O4) C, H, N; N calcd, 30.03; found, 29.55. 
9-(5-Ethylcarbamoyl--D-ribofuranosyl)-N6-methyl-2-(4-benzyl-1,2,3-triazol-1-yl)adenine 
(18). The reaction of compound 31 (70 mg, 0.19 mmol) with 3-phenyl-1-propyne (49µL, 0.56 
mmol) gave 35 mg (38 %) of compound 18 as a white solid. 1H NMR (300 MHz, DMSO-d6):  
0.87 (t, 3H, J = 7.5 Hz, CH3), 3.03-3.20 (m, 2H, N-CH2), 3.03 (d, 3H, 4.5 Hz, N6-CH3), 4.11 (s, 
2H, CH--Ph), 4.24 (m, 1H, H-3’), 4.32 (d, 1H, J = 2.1 Hz, H4’), 4.72 (m, 1H, H-2’), 5.59 (d, 1H, 
J = 6.6 Hz, 3’-OH), 5.69 (d, 1H, J = 4.5 Hz, 2’-OH), 6.03 (d, 1H, J = 6.9 Hz, H1’), 7.22 (m, 1H, 
Ph), 7.32 (d, 4H, J = 4.2 Hz, Ph), 8.06 (t, 1H, J = 5.7 Hz, NHCO), 8.38 (d, 1H, J = 4.1 Hz, N6-H), 
8.54 (s, 1H, H-8), 8.60 (s, 1H, H-5”);13NMR (300 MHz, DMSO-d6):  15.16 (CH3), 27.84 (N6-
CH3), 31.72 (CH2), 34.07 (N-CH2), 73.64 (C-2’ and C-3’), 84.98 (C-4’), 87.87 (C-1’), 119.91 (C-
5), 122.11 (C-5”), 126.93, 129.13, 129.22 and 140.07 (Ph), 140.48 (C-8), 147.05, 149.87 (C-4, C-
2 and C-4”), 156.12 (C-6), 169.71 (C=O); HRMS (ESI-MS) C22H26N9O4 [M+H]+: 480.2098 
found, 480.2107 calcd. Anal. (C22H25N9O4) C, H, N. 
2-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(5-ethylcarbamoyl--D-ribofuranosyl)-N6-
methyladenine (19). Compound 31 (60 mg, 0.17 mmol), sodium ascorbate (13 mg, 0.066 mmol) 
and CuSO4.5H2O (3.5 mg, 0.013 mmol) were suspended in 4 mL tBuOH:H2O (1:1). 3-
cyclopentyl-1-propyne (58 µL, 0.44 mmol) was subsequently added and the mixture was stirred 
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two d at room temperature. The 2-triazol-1-yl compound precipitated from the reaction medium. 
Water was added and the mixture was cooled overnight. The precipitate was filtered off and 
washed with water and hexane to obtain 19 as a white solid in 33 % yield. 1H NMR (300 MHz, 
DMSO-d6):  0.89 (t, 3H, CH3), 1.19-1.28 (m, 2H, cyclopentyl), 1.45-1.75 (m, 6H, cyclopentyl), 
2.15-2.25 (m, 1H, CH, cyclopentyl), 2.72 (d, 2H, J = 7.2 Hz, CH2), 3.06 (d, 3H, J = 4.5 Hz, N6-
CH3), 3.09-3.22 (m, 2H, N-CH2), 4.24 (dt, 1H, J = 1.5 and 4.8 Hz, H-3’), 4.33 (d, 1H, J = 2.1 Hz, 
H-4’), 4.71-7.76 (app q, 1H, J = 6.6 Hz, H-2’), 5.61 (d, 1H, J = 6.3 Hz, 2’-OH), 5.71 (d, 1H, J = 
4.8 Hz, 3’-OH), 6.03 (d, 1H, J = 6.9 Hz, H-1’), 8.10 (t, 1H, J = 5.7 Hz, NHCO), 8.40 (d, 1H, J = 
5.1 Hz, N6-H), 8.54 (s, 1H, H-8), 8.56 (s, 1H, H-5”); 13C NMR (300 MHz, DMSO-d6):  15.17 
(CH3), 25.36 (cyclopentyl), 27.85 (N6-CH3), 31.53 (cyclopentyl), 31.51 (CH2), 34.07 (CH2), 
73.63 and 73.56 (C-2’ and C-3’), 84.99 (C-4’), 87.93 (C-1’), 119.77 (C-5), 121.69 (C-5”), 141.51 
(C-8), 147.48 and 149.92 (C-2, C-4 and C-4”), 156.10 (C-6), 169.74 (C=O); HRMS (ESI-MS) 
C21H30N9O4 [M+H]+: 472.2415 found, 472.2420 calcd. Anal. (C21H29N9O4) C, H, N.  
N6-(5-Chloro-2-methoxybenzyl)-2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(-D-
ribofuranosyl)adenine (20). Compound 33 (100 mg, 0.22 mmol), sodium ascorbate (17 mg, 
0.086 mmol) and CuSO4.5H2O (3.5 mg, 0.017 mmol) were suspended in 4 mL H2O:tBuOH (1:1). 
3-Cyclopentyl-1-propyne (29 µL, 0.44 mmol) was subsequently added and the mixture was 
stirred two d at room temperature. The 2-triazol-1-yl compound precipitated from the reaction 
medium. Water was added and the mixture was cooled overnight. The precipitate was filtered off 
and washed with water and hexane to obtain 20 as a white solid in 59 % yield. 1H NMR (300 
MHz, DMSO-d6):  1.23-1.28 (m, 2H, cyclopentyl), 1.48-1.61 (m, 4H, cyclopentyl), 1.66-1.73 
(m, 2H, cyclopentyl), 2.15-2.25 (m, 1H, cyclopentyl), 2.72 (d, 2H, J = 7.2 Hz, CH2-cyclopentyl), 
3.56-3.61 (m, 1H, H-5’A), 3.66-3.71 (m, 1H, H-5’B), 3.97 (m, 1H, H-4’), 4.20 (m, 1H, H-3’), 
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4.64 (m, 1H, H-2’), 4.73 (br s, 2H, N6-CH2), 4.96 (t, 1H, J = 6.0 Hz, 5’-OH), 5.22 (d, 1H, J = 4.8 
Hz, 3’-OH), 5.48 (d, 1H, J = 5.7 Hz, 2’-OH), 5.95 (d, 1H, J = 6.3 Hz, H-1’), 7.04 (d, 1H, J = 9.0 
Hz, Ph), 7.25-7.29 (m, 2H, Ph), 8.40 (s, 1H, H-8), 8.81 (s, 1H, H-5”), 8.81 (br s, 1H, N6-H); 
13NMR (300 MHz, DMSO-d6):  25.36 (cyclopentyl), 31.54 (CH2), 32.54 (cyclopentyl), 38.86 
(CH2), 56.57 (OCH3), 62.13 (C-5’), 71.15 (C-3’), 74.37 (C-2’), 86.46 (C-4’), 88.07 (C-1’), 
113.15 (Ph), 119.58 (C-5), 121.37 (C-5”), 124.66, 128.23 and 129.93 (Ph), 141.37 (C-8), 147.40, 
149.66 and 150.12 (C-2,C-4 and C-4”), 155.51 (Ph), 156.33 (C-6); HRMS (ESI-MS) 
C26H32N8O5Cl [M+H]+: 571.2184 found, 571.2184 calcd. Anal. (C26H31N8O5Cl) C, H, N. 
2-Azido-N6-methyl-9-(-D-ribofuranosyl)adenine (23). Sodium ascorbate (19.4 mg; 0.098 
mmol) and CuSO4.5H2O (12.2 mg; 0.049 mmol) were added to a mixture of 22 (200 mg; 0.491 
mmol), sodium azide (38,3 mg; 0.589 mmol), L-proline (11,3 mg; 0.098 mmol) and sodium 
carbonate (10.4 mg; 0.098 mmol) in 10 mL H2O:tBuOH (1:1).  The reaction was stirred 
overnight at 65 °C and was monitored by 1H-NMR. 50 mL dilute NH4OH was added and the 
crude mixture extracted with ethyl acetate (3 x 60 mL). The organic layer was washed with brine 
(60 mL), dried over MgSO4, and purified on a silica gel column (CH2Cl2:MeOH, 95:5) to afford 
compound 23 as a slightly yellow solid in 66% yield. 1H NMR (300 MHz, DMSO-d6):  2.91 (d, 
3H, J = 4.4 Hz, N6-CH3), 3.48-3.55 (m, 1H, H-5’A), 3.58-3.66 (m, 1H, H-5’B), 3.90 (dd, 1H, J = 
3.8 and 7.3 Hz, H-4’), 4.10 (dd, 1H, J = 4.7 and 9.7 Hz, H3’), 4.53 (app q, 1H, J = 5.9 Hz, H-2’), 
5.04 (dd, 1H, J = 5.2 and 6.2 Hz, 5’-OH), 5.19 (d, 1H, J = 5.0 Hz, 3’OH), 5.43 (d, 1H, J = 6.2 Hz, 
2’-OH), 5.78 (d, 1H, J = 6.2 Hz, H-1’), 8.12 (d, J = 4.4 Hz, N6-H), 8.27 (s, 1H, H-8), small peaks 
from 1/6 tetrazole tautomeric form:  3.15 (d, 3H, J = 5.0 Hz, N6-CH3), 3.95 (d, H-4’), 4.15 (d, 
H-3’), 5.51 (d, 2’-OH), 5.94 (d, H-1’), 8.51(s, H-8); 13C NMR (300 MHz, DMSO-d6):  27.54 
(N6-CH3), 62.21 (C-5’), 71.17 (C-3’), 74.12 (C-2’), 86.35 (C-4’), 88.01 (C-1’), 118.07 (C-5), 
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139.99 (C-8), 156.06 and 156.20 (C-2 and C-6), small peaks from 1/6 tetrazole tautomeric form: 
 31.89 (N6-CH3), 61.79 (C-5’), 70.77 (C-3’), 74.37 (C-4’), 112.30 (C-12), 142.91 (C-11), 147.60 
(C-6); HRMS (ESI-MS) C11H15N8O4 [M+H]+: 323.1208 found, 323.1216 calcd. Anal. 
(C11H14N8O4) C, H, N. 
N6-Methyl-9-(-D-ribofuranosyl)-2-[2-trimethylsilylethyn-1-yl]adenine (24). Compound 22 
(500 mg, 1.23 mmol), CuI (12 mg, 0.062 mmol) and (Ph3P)3PCl2 were dissolved in 9 mL DMF. 
Triethylamine (205 µL, 1.47 mmol) and trimethylsilylacetylene (210 mg, 1.47 mmol) were added 
and the reaction mixture was stirred overnight. After solvent evaporation, the residue was 
dissolved in CH2Cl2 and filtered through a pad of Celite. Purification on a silica gel column 
(CH2Cl2:MeOH 95:5) yielded 305 mg (66%) of compound 23. 1H NMR (300 MHz, DMSO-d6):  
0.00 (9H, s, (CH3)3Si), 2.7, 3H, N6-CH3), 3.26-3.34 (m, 1H, H-5’A), 3.37-3.44 (m, 1H, H-5’B), 
3.68 (dd, 1H, J = 3.5 Hz, H-4’), 3.86 (dd, 1H, J = 3.4 and 8.2 Hz, H-3’), 4.23 (app q, 1H, J = 5.9 
Hz , H-2’), 4.87 (t, 1H, J = 5.0, 5’-OH), 4.94 (d, 1H, J =  4.99 Hz, 3’-OH), 5.21 (d, 1H, J = 6.2 
Hz, 2’-OH), 5.63 (d, 1H, J = 6.2 Hz, H-1’), 7.69 (br s, 1H, N6-H), 8.19 (s, 1H, H-8); HRMS (ESI-
MS) C16H24N5O4Si: [M+H]+: 378.1586 found; 378.1597 calcd. 
2-Ethynyl-N6-methyl-9-(-D-ribofuranosyl)purine (25). 300 mg  (0.8 mmol) of compound 24 
was dissolved in 7N ammonia in methanol and stirred for 2 h at 0 °C. After solvent evaporation, 
the residue was purified by silica gel chromatography (CH2Cl2:MeOH 95:5) to obtain 160 mg 
(65%) of derivative 25. 1H NMR (300 MHz, DMSO-d6):  2.91(s, 3H, N6-CH3), 3.48-3.56 (m, 
1H, H-5’A), 3.61-3.68 (m, 1H, H-5’B), 3.92 (m, 1H, H-4’), 4.02 (s, 1H, C≡CH), 4.11 (dd, 1H, J= 
5.0 and 8.2 Hz, H-3’), 4.53 (app q, 1H, J= 5.9 Hz, H-2’), 5.15 (m, 2H, 3’-OH and 5’-OH), 5.44 
(d, 1H, J= 6.15 Hz, 2’-OH), 5.84 (d, 1H, J= 6.16 Hz, H-1’), 7.95 (br s, 1H, N6-H), 8.40 (s, 1H, H-
8); HRMS (ESI-MS) C13H16N5O4: [ M+H]+: 306.1197 found; 306.1202 calcd. 
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1-Deoxy-1-(6-methylamino-2-iodo-9H-purin-9-yl)-2,3-O-isopropylidene--D-
ribufuranuronic acid (27). To a stirred solution of 3.8 g (8.5 mmol) of 26 in 560 mL H2O were 
added 1.4 g KOH and, dropwise, a solution of 4.03 g (25.5 mmol) of KMnO4 in 110 mL of H2O. 
The mixture was stirred in the dark for 20 h, cooled to 0 °C  and quenched with 30 mL 7% H2O2. 
The mixture was filtered through Celite, the filtrate was concentrated in vacuo and then acidified 
to pH 4 with 3N HCl. The resulting precipitate was filtered off and successively washed with 
water and ether to give 2.98 g (76%) of 27 as a white solid.  1H NMR (300 MHz, DMSO-d6): 
1.36 (s, 3H, CH3), 1.51 (s, 3H, CH3), 2.89 (d, 3H, J = 3.3 Hz, N6-CH3), 4.68 (d, 1H, J = 1.8 Hz, 
H-4’), 5.40 (d, 1H, J = 6.0 Hz, H-2’), 5.47 (dd, 1H, J = 6.0 and 1.8 Hz, H-3’), 6.28 (s, 1H, H-1’), 
8.08 (d, 1H, J = 3.3 Hz, N6-H), 8.16 (s, 1H, H-8); HRMS (ESI-MS) C14H16N5O5I: [M+H]+: 
462.0273 found; 462.0276 calcd. 
9-(5-Ethylcarbamoyl--D-ribofuranosyl)-2-iodo-N6-methyladenine (30). p-Nitrophenol (402 
mg, 2.89 mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (506 mg, 
2.65 mmol) were added to a solution of 27 (1.11 g, 2.41 mmol) in 10 mL dry DMF. The reaction 
mixture was stirred for 3 h at room temperature, cooled to 0 °C and 1.6 mL (24.1 mmol) of 
ethylamine was added. The solution turned yellow immediately and was further stirred for 1 h at 
room temperature. After evaporating the volatiles, the residue was partitioned between ethyl 
acetate  (3 x 100 mL) and H2O (100 mL). The organic layer was washed with brine (100 mL), 
dried over MgSO4 and concentrated to dryness. The residue was dissolved in 80% aquous TFA 
(20 mL) and stirred for 2 h at room temperature. The mixture was concentrated in vacuo, 
coevaporated several times with EtOH and purified by silica gel chromatography (CH2Cl2:MeOH 
96:4). Compound 30 was obtained as a white solid in 78 % yield (840 mg). 1H NMR (300 MHz, 
DMSO-d6):  1.05 (t, 3H, J = 7.2 Hz, CH3), 2.91 (d, 3H, J = 4.4 Hz, N6-CH3), 3.19-3.29 (m, 2H, 
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N-CH2), 4.16 (dt, 1H, J = 2.1 and 4.4 Hz, H-3’), 4.31 (d, 1H, J = 2.1 Hz, H-4’), 4.58 (app q, 1H, J 
= 5.6 Hz, H-2’), 5.59 (d, 1H, J = 6.5 Hz, 2’-OH), 5.71 (d, 1H, J = 4.7 Hz, 3’-OH),  5.92 (d, 1H, J 
= 7.1 Hz, H-1’), 8.12 (t, 1H, J = 5.5 Hz, NHCO), 8.19 (d, 1H, J = 4.4 Hz, N6-H), 8.38 (s, 1H, H-
8); HRMS (ESI-MS) C13H18N6O4I [M+H]+: 449.0429 found,  449.0436 calcd.  
2-Azido-9-(5-ethylcarbamoyl--D-ribofuranosyl)-N6-methyladenine (31). Sodium ascorbate 
(69 mg, 0.34 mmol) and CuSO4.5H2O (5.6 mg, 0.17 mmol) were added to a mixture of  30 (780 
mg, 1.74 mmol), sodium azide (226 mg, 3.48 mmol), L-proline (40 mg, 0.35 mmol) and sodium 
carbonate (37 mg, 0.35 mmol) in 20 mL H2O:tBuOH (1:1). The reaction was stirred for 2 d at 65 
°C and monitored by 1H-NMR. 100 mL dilute NH4OH was added and the crude mixture 
extracted with ethyl acetate (5 x 150 mL) and washed with brine (150 mL). The organic layer 
was dried over MgSO4 and purified on a silica gel column (CH2Cl2:MeOH 96:4) to afford 
compound 31 as a white solid in 79 % yield (500 mg). 1H NMR (300 MHz, DMSO-d6):  1.06 (t, 
3H, J = 7.2 Hz, CH3), 2.96 (d, 3H, J = 4.0 Hz, N6-CH3), 3.16-3.29 (m, 2H, N-CH2), 4.14 (dt, 1H, 
J = 1.8 and 4.8 Hz, H-3’), 4.29 (d, 1h, J = 1.8, H-4’), 4.53-4.59 (app q, 1H, J = 6.3 Hz, H-2’), 
5.52 (d, 1H, J = 6.3 Hz, 2’-OH), 5.68 (d, 1H, J = 4.8 Hz, 3’-OH), 5.90 (d, 1H, J = 7.2 Hz, H-1’), 
8.20 (d, 1H, J = 4.0 Hz, N6-H), 8.35 (s, 1H, H-8), 8.49 (t, 1H, J = 6.0 Hz, NHCO) small peaks 
from 1/5 tetrazole tautomeric form: 1.08-1.12 (t, 3H, J = 7.2 Hz, CH3), 4.34 (d, 1H, J = 2.1 Hz, 
H-4’), 4.67-4.73 (app q, 1H, J = 7.2 Hz, H-2’), 5.54 (d, 1H, J = 4.5 Hz, 2’-OH) 6.00 (d, 1H, J = 
7.2 Hz, H-1’);13NMR (300 MHz, DMSO-d6):  15.48 (CH3), 27.52 (N6-CH3), 33.94 (N-CH2), 
73.06 and 73.75 (C-2’ and C-3’), 85.15 (C-4’), 88.09 (C-1’), 118.36 (C-5), 140.69 (C-8), 156.032 
and 156.143 (C-2 and C-4) 169.79 (C-6); HRMS (ESI-MS) C13H18N9O4 [M+H]+:  364.1473 
found, 364.1481 calcd. Anal. (C13H17N9O4) C, H, N. 
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N6-(5-Chloro-2-methoxybenzyl)-2-iodo-9-(-D-ribofuranosyl)adenine (32) 
Compound 21 (1 g, 1.86 mmol) was dissolved in EtOH (30 mL). 5-chloro-2-
methoxybenzylammonium chloride (580 mg, 2.79 mmol) and Et3N (392 µL, 2.79 mmol) were 
added, and the solution was refluxed overnight. The mixture was concentrated to dryness, 
dissolved in 7N NH3 in methanol and stirred at room temperature for 2 h to deprotect the 2’-
hydroxyl group. The volatiles were removed under reduced pressure, and the residue was purified 
by silica gel column (CH2Cl2:MeOH, 97:3). The product, compound 32, was realized in 80 % 
yield. 1H NMR (300 MHz, DMSO-d6):  3.51-3.58 (m, 1H, H-5’A), 3.63-3.68 (m, 1H, H-5’B), 
3.85 (s, 3H, OCH3), 3.94 (m, 1H, H-4’), 4.13 (m, 1H, H-3’), 4.52-4.59 (m, 3H, N6-CH2 and H-
2’), 5.03 (t, 1H, J = 5.6 Hz, 5’-OH), 5.21 (d, 1H, J = 5.0 Hz, 3’-OH), 5.48 (d, 1H, J = 5.8 Hz, 2’-
OH), 5.83 (d, 1H, J = 6.2 Hz, H-1’), 7.03 (d, 1H, J = 8.8 Hz, Ph), 7.16 (d, 1H, J = 2.7 Hz, Ph), 
7.29 (dd, 1H, J = 2.7 and 8.8 Hz, Ph), 8.35 (s, 1H, H-8), 8.62 (br s, 1H, N6-H); HRMS (ESI-MS) 
C18H20N5O5ICl  [M+H]+:  548.0204 found, 548.0199 calcd. 
2-Azido-N6-(5-chloro-2-methoxybenzyl)-9-(-D-ribofuranosyl)adenine (33). Sodium 
ascorbate (14 mg, 0.073 mmol) and CuSO4.5H2O (9 mg, 0.037 mmol) were added to a mixture of 
32 (200mg, 0.365 mmol), sodium azide (47 mg, 0.73 mmol), L-proline (8 mg, 0.073 mmol) and 
sodium carbonate (8mg, 0.073 mmol) in 4 mL H2O:tBuOH (1:1). The reaction was stirred for 2 d 
at 65 °C and monitored by 1H-NMR. 10 mL dilute NH4OH was added and the crude mixture 
extracted with ethyl acetate (5 x 15 mL) and washed with brine (15 mL). The organic layer was 
dried over MgSO4 and purified on a silica gel column (CH2Cl2:MeOH 97:3) to afford compound 
33 as a white solid in 82 % yield. 1H NMR (300 MHz, DMSO-d6):  3.51-3.56 (m, 1H, H5’-A) , 
3.60-3.66 (m, 1H, H5’-B), 3.93 ( m, 1H, H 4’), 4.13 ( m, 1H, H-3’), 4.56-4.62 (m, 3H, N6-CH2 
and H-2’), 5.03 (t, 1H, J = 5.4 Hz, 5’-OH), 5.17 (d, 1H, J = 4.8 Hz, 3’-OH), 5.41 (d, 1H, J = 6.3 
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Hz, 2’-OH), 5.81 (d, 1H, J = 6.0 Hz, H-1’), 7.02 (d, 1H, J = 8.7 Hz, Ph), 7.15 (d, 1H, J = 3.0 Hz, 
Ph), 7.28 (dd, 1H, J = 2.7 and 8.7 Hz, Ph), 8.34 (s, 1H, H-8), 8.63 (br s, 1H, N6-H); 13C NMR 
(300MHz, DMSO-d6):  38.59 (CH2), 56.49 (OCH3), 62.19 (C-5’), 71.15 (C-3’), 74.13 (C-2’), 
86.36 (C-4’), 88.13 (C-1’), 113.02 (Ph), 119.58 (C-5), 124.29 (Ph), 128.10 (Ph), 129.93 (Ph), 
140.43 (C-8), 150.69 (C-4), 155.51 (Ph and C-2), 156.33 (C-6); HRMS (ESI-MS) C18H20N8O5Cl  
[M+H]+:  463.1248 found, 463.1245 calcd. Anal. (C18H19N8O5Cl) C, H, N. 
 
 
Cell culture and membrane preparation. CHO cells expressing recombinant human ARs or the 
rat A3AR were cultured in DMEM (Dulbecco’s modified Eagle’s medium) and F12 (1:1) 
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 µg/mL streptomycin, 
and 2 µmol/mL glutamine. After harvest and homogenization, the cells were centrifuged at 500 g 
for 10 min. The pellet was resuspended in 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM 
MgCl2 and 1 mM EDTA. The suspension was homogenized with an electric homogenizer for 10 
s, and was then recentrifuged at 20,000g for 20 min at 4 °C. The resulting pellets were 
resuspended in buffer containing 3 units/mL of adenosine deaminase, and the suspension was 
stored at -80 °C prior to the binding experiments. The protein concentration was measured using 
the Bradford assay.39 
 
Radioligand binding studies. For the A3AR binding experiments, the procedures were similar to 
those previously described.19 Briefly, each tube contained 100 µL of membrane suspension, 50 
µL of [125I]I-AB-MECA ([125I]N6-(4-Amino-3-iodobenzyl)adenosine-5-N-methyl-uronamide, 
final concentration 0.5 nM), and 50 µL of increasing concentrations of compounds in tris-HCl 
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buffer (50 mM, pH 7.4) containing 10 mM MgCl2, 1 mM EDTA. Non-specific binding was 
determined using 10 µM NECA (adenosine-5-N-ethyluronamide). The mixtures were incubated 
at 25 °C for 60 min. Binding reactions were terminated by filtration through Whatman GF/B 
filters under reduced pressure using a MT-24 cell harvester (Brandel, Gaithersburg, MD). Filters 
were washed three times with ice-cold buffer. Radioactivity was determined in a Beckman 5500B 
γ-counter. The binding of [3H]CCPA (2-chloro-N6-cyclopentyladenosine) to the recombinant 
hA1AR and the binding of [3H]CGS21680 (2-[p-(2-carboxyethyl)phenyl-ethylamino]-5-N-
ethylcarboxamido-adenosine) to the recombinant hA2AAR was performed as previously 
described.20,44 
 
Cyclic AMP accumulation assay. Intracellular levels of 3,5-cyclic AMP were measured by the 
competitive protein binding method.32 CHO cells expressing recombinant human40 ARs were 
harvested by trypsinization. After resuspension in the medium, cells were plated in 24-well plates 
in 0.5 mL medium/well. After 24 h the medium was removed and cells were washed three times 
with 1 mL/well of DMEM containing 50 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic 
acid, pH 7.4. Cells were then treated with agonists and/or test compounds in the presence of 
rolipram (10 µM) and adenosine deaminase (3 units/mL) and incubated at 37 °C. For the A3AR, 
after 45 min forskolin (10 µM) was added to the medium, and incubation was continued for an 
additional 15 min. The reaction was terminated upon removal of the medium, and the cells were 
lysed with 200 µL/well of 0.1 M ice-cold HCl. The cell lysate was resuspended and stored at -20 
°C. For determination of cyclic AMP production, protein kinase A (PKA) was incubated with 
[3H]cyclic AMP (2 nM) in K2HPO4/EDTA buffer (K2HPO4, 150 mM; EDTA, 10 mM), 20 µL of 
the cell lysate, and 30 µL 0.1 M HCl. Bound radioactivity was separated by rapid filtration 
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through Whatman GF/C filters under reduced pressure and washed once with cold buffer. Bound 
radioactivity was subsequently measured by scintillation spectrometry. Calculation of the relative 
maximal efficacy at the A3AR was determined at a fixed concentration of the nucleoside 
analogue (10 µM) and expressed as a relative percent of the effect of 10 µM NECA determined 
in each experiment, which typically reached ~50% inhibition of the forskolin stimulated cyclase.   
 
Molecular Modeling. All calculations were performed on a Silicon Graphics Octane2 
workstation (600 MHz IP30 processor, MIPS R14000). Compound 10, 2-(4-cyclopentylmethyl-
1,2,3-triazole)-N6-methyl-adenosine was constructed with the use of the Sketch Molecule of 
SYBYL 7.1 (Tripos Inc., 1699 South Hanley Rd., St. Louis, Missouri 63144, USA.). A grid 
search was performed, in which flexible bonds were rotated by 0, 180° for t1 (C5-C6-N6-CMe) at 
the N6 position, t2 (4O-4C-5C-5OH) at the 5-position and t3 (N3-C2-N1-N2) and by 60, 180, -
60° for t4 (N3-C4-CMe-CCyc) and t5 (C4-CMe-CCyc-CCyc) at the C2 position. The low-energy 
conformers from the grid search were re-optimized, removing all torsional constraints. Merck 
molecular force field (MMFF)41 and charges were applied with the use of distance-dependent 
dielectric constants and conjugate gradient method until the gradient reached 0.05 kcal • mol–1 • 
Å–1. After clustering the low-energy conformers from the result of the grid search, the 
representative ones from all groups were re-optimized by semi-empirical molecular orbital 
calculations with the PM3 method in the MOPAC 6.0 package.42    
 
A human A3AR model (PDB code: 1OEA) constructed by homology to the X-ray structure of 
bovine rhodopsin with 2.8 Å resolution (PDB ID: 1F88)38 was used for the docking study. All 
atom types were assigned by the Amber7_FF99 force field.43 Amber charges for protein and 
 35
MMFF charges for ligand were calculated. The starting geometry of the ligand conformation was 
chosen from the human A3AR complex model with Cl-IB-MECA,19 which was already validated 
by point-mutation. The ribose binding position was fixed, using an atom-by-atom fitting method 
for the carbon atoms of the ribose ring. To determine the binding region of the 2-(4-
cyclopentylmethyl-1,2,3-triazole) moiety at the adenine 2 position, the flexible bond defining a χ1 
(O-C1-N9-C4) angle was searched while docked within the putative binding cavity through 
various low energy conformers with diverse t1 to t5 angles, rotating by -60, -110, -160°, 
assuming an anti-conformation. Several conformations without any steric bump were selected for 
further optimization. The initial structures of all complexes were optimized using the Amber 
force field with a fixed dielectric constant of 4.0 and a terminating gradient of 0.05 kcal • mol–1 • 
Å–1.  
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SCHEME AND FIGURE LEGEND 
 
Scheme 1. Synthesis of 1,2,3-triazol-1-yl analogues of N6-methyl-adenosine 1 – 11. Reagents and 
conditions: (a) CH3NH2 in THF, 2 d; (b) CuSO4.5H2O, sodium ascorbate, L-proline, 
Na2CO3, NaN3, H2O:tBuOH 1:1, 60 °C; (c) CuSO4.5H2O, sodium ascorbate, alkyne, 
H2O:tBuOH 3:1, rt.  
Scheme 2. Azido/tetrazole tautomerism of a 2-substituted adenosine derivative 23.  
Scheme 3. Synthesis of 1,2,3-triazol-4-yl analogues of N6-methyl-adenosine 12 – 14. Reagents 
and conditions: (a) trimethylsilylacetylene, CuI, (Ph3P)3PdCl2, DMF; (b) 7N NH3 in 
MeOH, 0 °C; (c) CuSO4.5H2O, sodium ascorbate, alkyne, H2O:tBuOH 3:1, rt.  
Scheme 4. Synthesis of 1,2,3-triazol-1-yl analogues of N6-methyl-adenosine-5-N-
ethyluronamide 15 – 19. Reagents and conditions: (a) KMnO4, KOH, rt, 20h; (b) p-
nitrophenol, EDCI, DMF, rt; (c) ethylamine; (d) 80% TFA/H2O; (e) CuSO4.5H2O, 
sodium ascorbate, L-proline, Na2CO3, NaN3, H2O:tBuOH 1:1, 60 °C; (f) CuSO4.5H2O, 
sodium ascorbate, alkyne, H2O:tBuOH 1:1, rt. 
Scheme 5. Synthesis of compound 20, 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-N6-(2-chloro-5-
methoxybenzyl)-adenosine. Reagents and conditions: (a) 2-chloro-5-methoxy-
benzylammonium chloride, EtN3, EtOH, reflux; (b) CuSO4.5H2O, sodium ascorbate, L-
proline, Na2CO3, NaN3, H2O:t-BuOH 1:1, 60 °C; (c) CuSO4.5H2O, sodium ascorbate, 
alkyne, H2O:tBuOH 1:1, rt. 
 
Figure 1. A) Docking complexes of compound 10, 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-
N6-methyl-adenosine. B) Superimposition of Cl-IB-MECA in red and compound 10 in 
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color by atom type. Residues that were within 5 Å proximity to the ligand in this 
putative binding site were: L91 (3.33), T94 (3.36), H95 (3.37), Q167 (EL2), F168 
(EL2), M172 (EL2), S181 (5.42), M177 (5.38), V178 (5.39), F182 (5.43), W243 (6.48), 
L246 (6.51), S247 (6.52), N250 (6.55), C251 (6.56), I268 (7.39), S271 (7.42), and H272 
(7.43). The ligand is represented by a ball-and-stick model. The H-bonds are indicated 
with yellow dots. Using MOLCAD ribbon surface program, the A3AR is shown in a 
ribbon model with different colors for each TM (TM1: red, TM2: orange, TM3: yellow, 
TM4: green, TM5: cyan, TM6: blue, TM7: purple, H8: violet). 
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Figure 1. 
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Table 1 Binding affinities of adenosine derivatives at human A1, A2A and A3ARs expressed in 
CHO cells and relative efficacy at the A3AR.a 
N
NN
N
NH
O
OHOH
R1
R3
N N
N R2
N
NN
N
NH
O
OHOH
R1 N
R3
N
N
R2
1-11, 15-20 12-14
N
NN
N
NH
O
OHOH
R1
R3
23, 31, 33
N3
 
  R1 R2 R3 Ki (nM) or (% inhibition) at 10µM  %Efficacyb 
       hA1 hA2A hA3  hA3
1 CH2OH H CH3 1000±30 (13±3%) 10.4±0.2 41±6 
2 CH2OH ethyl CH3 2920±910 (18%) 13.8±3.3 23c 
3 CH2OH butyl CH3 848±76 (23%) 11.7±3.1 3±8 
4 CH2OH 2-hydroxyethyl CH3 1270±260 (14%) 45.0±4.4 25c 
5 CH2OH dimethylaminomethyl CH3 3800±600 (6%) 117±25 8c 
6 CH2OH phenyl CH3 (36%) (5%) 14.9±1.7 14±8 
7 CH2OH pyridin-2-yl CH3 1970±210 (40%) 10.3±1.5 11±4 
8 CH2OH 4-propoxyphenyl CH3 (49%) (14%) 25.2±2.6 31c
9 CH2OH benzyl CH3 589±55 (20%) 9.5±0.7 -1±5 
10 CH2OH cyclopentylmethyl CH3 335±13 (39%) 1.3±0.4 -5±7 
11 CH2OH cyclohexylmethyl CH3 1430±60 (16±1%) 21.3±8.1 2±5 
12 CH2OH benzyl CH3 770±210 (21±5%) 53.9±6.6 2±3 
13 CH2OH 3-methoxybenzyl CH3 957±65 (43±10%) 86.1±3.8 -1±3 
14 CH2OH 3-Cl-benzyl CH3 956±6 (39±10%) 81.1±5.0 0±5 
15 C2H5NHCO H CH3 590±70 (18±3%) 2.1±0.1 102±5 
16 C2H5NHCO butyl CH3 750±110 (43±1%) 5.6±0.2 89±3 
17 C2H5NHCO pyridin-2-yl CH3 1640±90 (45±12%) 1.8±0.6  90±7 
18 C2H5NHCO benzyl CH3 510±50 (33±2%) 2.8±1.3 86±5 
19 C2H5NHCO cyclopentylmethyl CH3 1250±150 (36±7%) 11.5±1.4 83c 
20 CH2OH cyclopentylmethyl 2-Cl-5-MeO-Bn  830±40 6000 18±11 -6±3 
23 CH2OH - CH3 230±10 (23%) 10.8±3.1 84±9 
31 C2H5NHCO - CH3 429±55 (18±3%) 11.4±4.2 112c 
33 CH2OH - 2-Cl-5-MeO-Bn 60±10 1800±500 1.4±0.1 44±5 
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a)  All A3AR experiments were performed using cells stably transfected with cDNA encoding 
one of the human ARs. Binding at human A1, A2A, and A3ARs in this study was carried out as 
described in Methods using [3H]CCPA, [3H]CGS 21680 or [125I]AB-MECA as radioligand. 
Values from the present study are expressed as Ki values (mean±s.e.m., n = 3, unless noted), or as 
percent displacement of radioligand.  
b)   % Activation at 10 µM, relative to cyclic AMP inhibitory effect of 10 µM NECA = 
100%. Cl-IB-MECA was also a full agonist (100%) in this assay.  
c) n = 2. 
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